NASDAQ: VRDNViridian Therapeutics Inc Stock
$12.70-0.33 (-2.53%)
Updated Apr 25, 2024
VRDN Price
$12.70
Fair Value Price
$1.79
Market Cap
$797.15M
52 Week Low
$10.93
52 Week High
$28.99
P/E
-2.39x
P/B
1.8x
P/S
3,104.38x
PEG
N/A
Dividend Yield
N/A
Revenue
$314.00k
Earnings
-$237.73M
Gross Margin
100%
Operating Margin
-75,123.25%
Profit Margin
-75,711.5%
Debt to Equity
0.11
Operating Cash Flow
-$184M
Beta
0.64
Next Earnings
Jun 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A
VRDN Overview
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how VRDN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
VRDN ($12.70) is overvalued by 608.86% relative to our estimate of its Fair Value price of $1.79 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
VRDN ($12.70) is not significantly undervalued (608.86%) relative to our estimate of its Fair Value price of $1.79 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
VRDN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more VRDN due diligence checks available for Premium users.
Be the first to know about important VRDN news, forecast changes, insider trades & much more!
VRDN News
Valuation
VRDN fair value
Fair Value of VRDN stock based on Discounted Cash Flow (DCF)
Price
$12.70
Fair Value
$1.79
Overvalued by
608.86%
VRDN ($12.70) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
VRDN ($12.70) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
VRDN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
VRDN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.39x
Industry
15.41x
Market
40.97x
VRDN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.8x
Industry
5.8x
VRDN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
VRDN's financial health
Profit margin
Revenue
$72.0k
Net Income
-$66.9M
Profit Margin
-92,861.1%
VRDN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
VRDN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$490.4M
Liabilities
$48.4M
Debt to equity
0.11
VRDN's short-term assets ($486.48M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VRDN's short-term assets ($486.48M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VRDN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
VRDN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$38.0M
Investing
-$169.7M
Financing
$198.9M
VRDN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
VRDN vs Biotech Stocks
Viridian Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.